These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29791043)

  • 21. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 22. Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
    Xu L; Shadman M; Flinn IW; Levy MY; Porter R; Burke JM; Zafar SF; Cultrera JL; Misleh J; Kingsley EC; Yimer HA; Freeman B; Chaudhry A; Tumula PK; Gandhi MD; Crescenzo R; By K; Cohen A; Chen DY; Idoine A; Manda S; Sharman JP; Ramakrishnan V
    Haematologica; 2024 Jul; 109(7):2284-2289. PubMed ID: 38268449
    [No Abstract]   [Full Text] [Related]  

  • 23. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
    JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
    [No Abstract]   [Full Text] [Related]  

  • 24. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
    UK CLL Forum
    Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
    Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
    J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P
    Am J Ther; 2024 Jul-Aug 01; 31(4):e453-e455. PubMed ID: 38305826
    [No Abstract]   [Full Text] [Related]  

  • 28. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 29. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
    Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
    Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
    [No Abstract]   [Full Text] [Related]  

  • 30. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
    Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
    [No Abstract]   [Full Text] [Related]  

  • 34. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
    Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
    Ito Y; Makita S; Maeshima AM; Hatta S; Suzuki T; Yuda S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Intern Med; 2018 Aug; 57(16):2395-2398. PubMed ID: 29526963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pirtobrutinib in relapsed or refractory CLL and SLL.
    Woyach JA
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):230-231. PubMed ID: 38805315
    [No Abstract]   [Full Text] [Related]  

  • 38. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
    Mehraban Far P; Rullo J; Farmer J; Urton T
    Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant.
    Khalid M; Khattak F; Ramu V
    Am J Ther; 2018; 25(6):e768-e769. PubMed ID: 29916856
    [No Abstract]   [Full Text] [Related]  

  • 40. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.